This phenomenon of ‘too much’ or ‘too little’ of a pathway or gene leading to similar outcomes has been seen before in MECP-2 gain and loss of function as well as in Timothy syndrome (Birey et al., 2022; Peters et al., 2013; Ramocki et al., 2010). This evidence concerns the gene MECP2 and Timothy syndrome.